<?xml version='1.0' encoding='utf8'?>
<text id="AMALGUM_academic_cholesterol" title="ER-Negative Breast Cancer Is Highly Responsive to Cholesterol Metabolite Signalling" shortTitle="cholesterol" author="Samantha  A Hutchinson, Priscilia Lianto, Hanne Roberg-Larsen, Sebastiano Battaglia, Thomas  A Hughes, James  L Thorne" type="academic" dateCollected="2019-11-03" sourceURL="https://www.mdpi.com/2072-6643/11/11/2618/htm" speakerList="none" speakerCount="0">
<head>
<s type="frag">
1.	LS	1.
Introduction	NN	introduction
</s>
</head>
<p>
<s type="decl">
Cholesterol	NN	cholesterol
is	VBZ	be
predominantly	RB	predominantly
synthesized	VBN	synthesize
de	NNP	de
novo	NN	novo
in	IN	in
the	DT	the
liver	NN	liver
with	IN	with
lesser	JJR	lesser
amounts	NNS	amount
obtained	VBN	obtain
from	IN	from
the	DT	the
diet	NN	diet
.	.	.
</s>
<s type="decl">
Dietary	JJ	dietary
intake	NN	intake
,	,	,
de	NN	de
novo	JJ	novo
synthesis	NN	synthesis
,	,	,
metabolism	NN	metabolism
and	CC	and
excretion	NN	excretion
,	,	,
combine	VBP	combine
to	TO	to
balance	VB	balance
circulating	VBG	circulate
cholesterol	NN	cholesterol
levels	NNS	level
ensuring	VBG	ensure
extra-hepatic	JJ	extra-hepatic
tissues	NNS	tissue
are	VBP	be
sufficiently	RB	sufficiently
equipped	VBN	equip
to	TO	to
produce	VB	produce
a	DT	a
range	NN	range
of	IN	of
metabolites	NNS	metabolite
including	VBG	include
steroid	NN	steroid
hormones	NNS	hormone
,	,	,
bile	NN	bile
acids	NNS	acid
and	CC	and
seco-steroids	NNS	seco-steroid
.	.	.
</s>
<s type="decl">
Side-chain	JJ	Side-chain
hydroxycholesterols	NNS	hydroxycholesterol
(	-LRB-	(
scOHCs	NNS	scohcs
)	-RRB-	)
are	VBP	be
typically	RB	typically
formed	VBN	form
through	IN	through
hydroxylation	NN	hydroxylation
of	IN	of
cholesterol	NN	cholesterol
by	IN	by
specialized	VBN	specialize
members	NNS	member
of	IN	of
the	DT	the
Cytochrome	NNP	Cytochrome
P450	NNP	P450
family	NN	family
,	,	,
which	WDT	which
bind	VBP	bind
and	CC	and
activate	VBP	activate
the	DT	the
Liver	NNP	Liver
X	NNP	X
Receptor-alpha	NNP	Receptor-alpha
(	-LRB-	(
LXRA	NNP	LXRA
;	:	;
gene	NN	gene
name	NN	name
<hi rend="italic">
NR1H3	NNP	NR1H3
</hi>
)	-RRB-	)
and	CC	and
beta	NN	beta
(	-LRB-	(
LXRB	NNP	LXRB
;	:	;
gene	NN	gene
name	NN	name
<hi rend="italic">
NR1H2	NNP	NR1H2
</hi>
)	-RRB-	)
transcription	NN	transcription
factors	NNS	factor
.	.	.
</s>
<s type="decl">
LXR	NNP	LXR
target	NN	target
genes	NNS	gene
are	VBP	be
typically	RB	typically
involved	VBN	involve
in	IN	in
cholesterol	NN	cholesterol
and	CC	and
fatty	JJ	fatty
acid	NN	acid
metabolism	NN	metabolism
.	.	.
</s>
<s type="decl">
In	IN	in
normal	JJ	normal
tissue	NN	tissue
,	,	,
expression	NN	expression
of	IN	of
LXRA	NNP	LXRA
is	VBZ	be
inducible	JJ	inducible
in	IN	in
the	DT	the
liver	NN	liver
,	,	,
intestine	NN	intestine
,	,	,
macrophages	NNS	macrophage
and	CC	and
adipocytes	NNS	adipocyte
,	,	,
whilst	IN	whilst
expression	NN	expression
of	IN	of
LXRB	NNP	LXRB
is	VBZ	be
more	RBR	more
ubiquitous	JJ	ubiquitous
.	.	.
</s>
<s type="decl">
As	RB	as
well	RB	well
as	IN	as
differences	NNS	difference
in	IN	in
expression	NN	expression
of	IN	of
LXRA	NNP	LXRA
and	CC	and
LXRB	NNP	LXRB
,	,	,
local	JJ	local
concentrations	NNS	concentration
of	IN	of
the	DT	the
scOHCs	NNS	scohcs
differ	VBP	differ
considerably	RB	considerably
between	IN	between
tissues	NNS	tissue
,	,	,
and	CC	and
relative	JJ	relative
to	IN	to
each	DT	each
other	JJ	other
,	,	,
sometimes	RB	sometimes
by	IN	by
as	RB	as
much	RBR	much
as	IN	as
<date when="1000">
1000-fold	CD	1000-fold
</date>
and	CC	and
variance	NN	variance
can	MD	can
also	RB	also
depend	VB	depend
on	IN	on
disease	NN	disease
status	NN	status
.	.	.
</s>
<s type="decl">
Furthermore	RB	furthermore
,	,	,
the	DT	the
different	JJ	different
scOHCs	NNS	scohcs
have	VBP	have
varying	VBG	vary
capacities	NNS	capacity
to	TO	to
activate	VB	activate
LXR-mediated	VBN	lur-mediate
transcription	NN	transcription
,	,	,
imposing	VBG	impose
an	DT	a
element	NN	element
of	IN	of
selective	JJ	selective
modulation	NN	modulation
onto	IN	onto
signalling	NN	signalling
.	.	.
</s>
<s type="decl">
26-OHC	CD	26-OHC
(	-LRB-	(
commonly	RB	commonly
referred	VBN	refer
to	IN	to
as	IN	as
27-OHC	CD	27-ohc
)	-RRB-	)
for	IN	for
example	NN	example
is	VBZ	be
the	DT	the
most	RBS	most
abundant	JJ	abundant
scOHC	NN	scOHC
,	,	,
but	CC	but
is	VBZ	be
a	DT	a
relatively	RB	relatively
weak	JJ	weak
LXR	NNP	LXR
agonist	NN	agonist
.	.	.
</s>
<s type="decl">
Moreover	RB	moreover
,	,	,
there	EX	there
is	VBZ	be
little	JJ	little
difference	NN	difference
in	IN	in
scOHC	NN	scOHC
concentrations	NNS	concentration
between	IN	between
breast	NN	breast
cancer	NN	cancer
subtypes	NNS	subtype
.	.	.
</s>
</p>
<p>
<s type="decl">
Transcriptional	JJ	Transcriptional
activity	NN	activity
of	IN	of
the	DT	the
LXRs	NNS	lur
,	,	,
like	IN	like
the	DT	the
other	JJ	other
members	NNS	member
of	IN	of
the	DT	the
Nuclear	NNP	nuclear
Receptor	NNP	Receptor
(	-LRB-	(
NR	NNP	NR
)	-RRB-	)
superfamily	NN	superfamily
,	,	,
is	VBZ	be
not	RB	not
just	RB	just
regulated	VBN	regulate
by	IN	by
ligand	NN	ligand
bioavailability	NN	bioavailability
;	:	;
chromatin	NN	chromatin
environment	NN	environment
,	,	,
cross-talk	NN	cross-talk
and	CC	and
competition	NN	competition
for	IN	for
response	NN	response
element	NN	element
binding	NN	binding
with	IN	with
other	JJ	other
NRs	NNS	nR
,	,	,
as	RB	as
well	RB	well
as	IN	as
cell-	JJ	cell-
and	CC	and
tissue-type	NN	tissue-type
dependent	JJ	dependent
expression	NN	expression
of	IN	of
cofactors	NNS	cofactor
are	VBP	be
also	RB	also
key	JJ	key
mediators	NNS	mediator
.	.	.
</s>
<s type="decl">
For	IN	for
example	NN	example
,	,	,
the	DT	the
expression	NN	expression
of	IN	of
corepressors	NNS	corepressor
such	JJ	such
as	IN	as
NCOR1	NNP	NCOR1
and	CC	and
NCOR2/SMRT	NNP	Ncorvorsm
determine	VBP	determine
how	WRB	how
several	JJ	several
cancers	NNS	cancer
respond	VBP	respond
to	IN	to
nutritive	JJ	nutritive
ligands	NNS	ligand
.	.	.
</s>
<s type="decl">
LXRA	NNP	LXRA
has	VBZ	have
a	DT	a
100-fold	CD	100-fold
higher	JJR	high
binding	NN	binding
affinity	NN	affinity
than	IN	than
LXRB	NNP	LXRB
for	IN	for
the	DT	the
corepressors	NNS	corepressor
NCOR1	NNP	NCOR1
and	CC	and
NCOR2	NNP	NCOR2
and	CC	and
deregulation	NN	deregulation
of	IN	of
these	DT	this
corepressors	NNS	corepressor
allows	VBZ	allow
prostate	NN	prostate
and	CC	and
bladder	NN	bladder
cancer	NN	cancer
cells	NNS	cell
to	TO	to
evade	VB	evade
cancer	NN	cancer
suppressive	JJ	suppressive
signals	NNS	signal
of	IN	of
Vitamin	NNP	Vitamin
D	NNP	D
(	-LRB-	(
through	IN	through
repression	NN	repression
of	IN	of
Vitamin	NNP	Vitamin
D	NNP	D
Receptor	NNP	Receptor
(	-LRB-	(
VDR	NNP	VDR
)	-RRB-	)
)	-RRB-	)
and	CC	and
omega-3	NN	omega-3
fatty	NN	fatty
acids	NNS	acid
(	-LRB-	(
through	IN	through
repression	NN	repression
of	IN	of
peroxisome	NN	peroxisome
proliferator-activated	NN	proliferator-activated
receptors	NNS	receptor
(	-LRB-	(
PPARs	NNS	ppar
)	-RRB-	)
)	-RRB-	)
by	IN	by
impairing	VBG	impair
sensitivity	NN	sensitivity
to	IN	to
ligand	NN	ligand
.	.	.
</s>
<s type="decl">
Simply	RB	simply
measuring	VBG	measure
scOHC	NN	scOHC
concentrations	NNS	concentration
does	VBZ	do
not	RB	not
sufficiently	RB	sufficiently
determine	VB	determine
their	PRP$	their
contributions	NNS	contribution
to	IN	to
LXR	NNP	LXR
signalling	NN	signalling
;	:	;
concentration	NN	concentration
and	CC	and
activation	NN	activation
potential	NN	potential
should	MD	should
be	VB	be
assessed	VBN	assess
in	IN	in
combination	NN	combination
.	.	.
</s>
</p>
<p>
<s type="decl">
In	IN	in
cancer	NN	cancer
,	,	,
the	DT	the
function	NN	function
of	IN	of
the	DT	the
scOHC-LXR	NNP	scOHC-LXR
signalling	NN	signalling
axis	NN	axis
appears	VBZ	appear
site	NN	site
specific	JJ	specific
as	IN	as
both	CC	both
tumour	NN	tumour
suppressive	NN	suppressive
and	CC	and
promoting	VBG	promote
roles	NNS	role
have	VBP	have
been	VBN	be
described	VBN	describe
.	.	.
</s>
<s type="decl">
For	IN	for
example	NN	example
,	,	,
scOHC-LXR	NNP	scOHC-LXR
signalling	NN	signalling
impairs	VBZ	impair
invasion	NN	invasion
and	CC	and
angiogenesis	NN	angiogenesis
in	IN	in
melanoma	NN	melanoma
and	CC	and
is	VBZ	be
anti-proliferative	JJ	anti-proliferative
in	IN	in
lung	NN	lung
cancer	NN	cancer
in	IN	in
vivo	NN	vivo
,	,	,
as	IN	as
it	PRP	it
is	VBZ	be
in	IN	in
almost	RB	almost
every	DT	every
cancer	NN	cancer
cell	NN	cell
line	NN	line
studied	VBN	study
in	IN	in
vitro	NN	vitro
.	.	.
</s>
<s type="decl">
In	IN	in
Oestrogen	NNP	Oestrogen
Receptor	NNP	Receptor
(	-LRB-	(
ER)-positive	NNP	ER)-positive
Breast	NNP	Breast
Cancer	NNP	Cancer
(	-LRB-	(
BCa	NNP	BCa
)	-RRB-	)
however	RB	however
26-OHC	CD	26-OHC
promotes	VBZ	promote
growth	NN	growth
in	IN	in
vivo	NN	vivo
via	IN	via
ER-alpha	FW	ER-alpha
.	.	.
</s>
<s type="frag">
In	IN	in
ER-negative	NNP	ER-negative
BCa	NNP	BCa
</s>
<s type="decl">
26-OHC	CD	26-OHC
drives	VBZ	drive
the	DT	the
epithelial-to-mesenchymal	JJ	epithelial-to-mesenchymal
transition	NN	transition
and	CC	and
promotes	VBZ	promote
colonization	NN	colonization
of	IN	of
metastatic	JJ	metastatic
sites	NNS	site
in	IN	in
through	IN	through
mobilization	NN	mobilization
of	IN	of
γδ-T	NN	γδ-T
cells	NNS	cell
.	.	.
</s>
<s type="decl">
Furthermore	RB	furthermore
,	,	,
concentrations	NNS	concentration
of	IN	of
several	JJ	several
scOHCs	NNS	scohcs
are	VBP	be
altered	VBN	alter
in	IN	in
BCa	NNP	BCa
relative	JJ	relative
to	IN	to
normal	JJ	normal
tissue	NN	tissue
,	,	,
and	CC	and
25-OHC	NNP	25-OHC
is	VBZ	be
elevated	VBN	elevate
in	IN	in
the	DT	the
circulation	NN	circulation
of	IN	of
BCa	NN	BCa
patients	NNS	patient
who	WP	who
have	VBP	have
relapsed	VBN	relapse
compared	VBN	compare
to	IN	to
those	DT	this
with	IN	with
primary	JJ	primary
disease	NN	disease
.	.	.
</s>
</p>
<p>
<s type="decl">
We	PRP	we
recently	RB	recently
evaluated	VBD	evaluate
LXR	NNP	LXR
ligand	NN	ligand
bio-availability	NN	bio-availability
in	IN	in
a	DT	a
small	JJ	small
BCa	NNP	BCa
cohort	NN	cohort
and	CC	and
found	VBD	find
large	JJ	large
inter	JJ	inter
tumoural	JJ	tumoural
heterogeneity	NN	heterogeneity
in	IN	in
oxysterol	NN	oxysterol
content	NN	content
,	,	,
but	CC	but
no	DT	no
difference	NN	difference
in	IN	in
ligand	NN	ligand
concentrations	NNS	concentration
between	IN	between
tumour	NN	tumour
subtypes	NNS	subtype
.	.	.
</s>
<s type="decl">
Systematic	JJ	systematic
evaluation	NN	evaluation
of	IN	of
scOHC	NN	scOHC
bioavailability	NN	bioavailability
and	CC	and
activation	NN	activation
potential	NN	potential
,	,	,
coupled	VBN	couple
with	IN	with
analysis	NN	analysis
of	IN	of
NR	NN	NR
cofactor	NN	cofactor
expression	NN	expression
between	IN	between
BCa	NNP	BCa
subtypes	NNS	subtype
has	VBZ	have
not	RB	not
been	VBN	be
performed	VBN	perform
previously	RB	previously
.	.	.
</s>
<s type="decl">
Given	VBN	give
the	DT	the
prognostic	JJ	prognostic
and	CC	and
therapeutic	JJ	therapeutic
value	NN	value
of	IN	of
stratifying	VBG	stratify
BCa	NNP	BCa
by	IN	by
hormone	NN	hormone
receptor	NN	receptor
status	NN	status
,	,	,
further	JJ	further
delineation	NN	delineation
of	IN	of
the	DT	the
pathways	NNS	pathway
that	WDT	that
are	VBP	be
altered	VBN	alter
between	IN	between
these	DT	this
subtypes	NNS	subtype
,	,	,
such	JJ	such
as	IN	as
scOHC-LXR	NNP	scOHC-LXR
signalling	NN	signalling
,	,	,
may	MD	may
help	VB	help
advance	VB	advance
understanding	NN	understanding
about	IN	about
the	DT	the
emerging	VBG	emerge
roles	NNS	role
of	IN	of
cholesterol	NN	cholesterol
metabolism	NN	metabolism
in	IN	in
cancer	NN	cancer
and	CC	and
improve	VB	improve
outcomes	NNS	outcome
for	IN	for
patients	NNS	patient
.	.	.
</s>
</p>
</text>